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Pharmacology is the science that deals with the effect of chemical 
agents upon living cells. The history of pharmacology as a discipline 
goes back as far as the primitive people who discovered the relationship 
between certain plants and their affect on certain disease states. This 
period of ancient pharmacology was characterized by empiric observations 
in the use of crude drug preparations. Today's period of modern pharma-
cology is based on experimental investigations that are designed to show 
the site and mode of action of chemical agents, i.e., drugs. These 
chemical agents may occur naturally within the cell's environment or may 
be a synthetic component of the cell's environment. The primary concern 
of the pharmacologist is the effect of these agents on metabolic pro-
cesses of organisms. This is most often achieved by studying these 
aspects in experimental animals and then applying what is.learned from 
the studies to the use of the drug in man. ·Because of this comparative 
nature of studying the affects of drugs, be they natural or synthetic 
compounds, this area pf pharmacology is often referred to as comparative 
pharmacology. 
The tremendous gains that have been made most recently in pharma-
cology are due primarily to the developments of other basic sciences 
that have enhanced our understanding of the basic framework by which 
organisms exist. Most often when a drug is being studied, valuable 
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contributions come from cell biologists, biochemists, ~nd pathalogists 
as well as many others. The contributions of these scientists allow for 
an enhanced knowledge of the pharmacodynamics of the drug. This area of 
pharmacodynamics deals with how a drug is affecting an organism or cell 
at the biochemical and physiological level. Any study of this type 
requires knowledge of how the drug is absorbed, distributed, metabolized 
and excreted by the organism. The evidence from these studies indicates 
that there is a strong correlation between the chemical structure of the 
agent and the effects it elicits. With this type of information, an 
organic chemist is able to design a drug with predictable actions. The 
final goal of these chemists is to produce organic compounds that have 
a high specificity for the invading organism with little or no effect 
on the host. 
This concept of high specificity for the invading organism and low 
specificity for the host is very important in pharmacology. Unfortu-
nately, this is not the case for most of the drugs employed in modern 
therapeutics. For this reason there is a division of pharmacology that 
deals with the toxicology of drugs. This area of pharmacology that 
works to control the toxicities associated with the administration of 
therapeutic agents is one that cannot be taken lightly. Through the use 
of comparative pharmacology, it is possible to determine the toxic 
effects of drugs on experimental animals and then to predict how the 
drug will affect the host upon administration of the drug. By changing 
the substituents present on the basic drug molecule and studying the 
variance of effects accompanying each of these, it is possible to iso-
late those chemical substituents that are toxic to the hosts. This type 
of information is a valuable tool to the organic chemist trying to 
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synthesize drugs with low toxicities in the host. Despite all the work 
that has been done in this area, there are still many drugs used thera-
peutically whose toxicities cannot be altered without a concomitant loss 
of therapeutic effectiveness. For this reason it is imperative that 
anyone dispensing or using drugs be aware of their potential danger and 
the signs associated with the toxic affects of the drug. Meanwhile 
much research will continue in the field of pharmacology so that one day 
i't may be possible to alleviate the adverse reactions accompanying many 
of these drugs. 
Absorption, Distribution and Excretion 
of Drugs 
Perhaps the most important characteristic associated with any drug 
is how it is absorbed from the site of administration. The bodies of 
man and animal have within them a number of permeability barriers. How 
the drug crosses these barriers determines how effective the d~ug will 
be against an invading organism. Extensive research in pharmacodynam-
ics has shown that the absorbance of a drug is dependent on conditions 
of pH, solubility of the drug in solution, solubility of the drug in 
lipid, and the amount of the drug present at the site of absorption. 
Drugs exist as either organic acids or ~rganic bases. As a result 
they have pK values associated with them. If the pH of the solution the 
drug is dissolved in is below that of the pK value, the drug will be 
primarily in the nonionized form. If the pH of the solution is higher 
than that of the pK value, the drug will be primarily in the ionized 
form (13, 19, 1). Due to the characteristics of absorptive membranes 
only the nonionized fraction of the drug will pass through the membrane 
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if it is soluble in lipid. For this reason it is the nonionized, lipid 
soluble fraction of the drug that represents the active moiety of the 
drug. 
There are three ways the drug can cross the absorbing membrane. 
First, the lipid soluble nonionized form of the drug may simply diffuse 
across the membrane (13, 1, 25). Second, the active form of the drug 
may be "carried" from one side of the membrane to the other. Thirdly, 
the drug moieties may pass through pores within the membrane structure 
(12). The absorption mechanisms involving diffusion of the lipid solu-
ble fraction of drug and the passage of drug moieties through pores of 
the membrane respond to a concentration gradient. That is, the drug 
form will move in a direction of high concentration to a lower concen-
tration of itself. The absorption mechanism involving a carrier 
associated with the membrane may or may not respond to a concentration 
gradient. If the carrier responds to a concentration gradient across 
the membrane, carrying the active moiety of the drug from a region that 
has less of this drug form present, then the absorption mechanism is 
termed facilitated diffusion (22). On the other hand, if the carrier is 
concentrating the active moiety on one side of the membrane, i.e., is 
carrying the drug form to a region that has·a greater number of the 
transported drug form, then the absorption mechanism is termed active 
transport (16). To determine by which absorptive mechanism a drug 
crosses the absorptive membrane, an analysis of the kinetics of absorp-
tion must be performed. Studies of this type surpass the scope of this 
paper, but nevertheless the knowledge of how the active moiety of the 
drug crosses the absorptive membrane is important when considering how 
much of a drug should be given to be therapeutic. 
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If the pH determines what state the drug predominates in solution 
according to the pK value of the drug and for all therapeutic purposes 
the nonionized fraction of the drug is the only active form of the drug 
it is logical to choose the drug of choice by matching it with the pH 
of the solution it will be dissolved in. All that is needed is a drug 
with a pKa value that corresponds favorably to the pH of the fluid sur-
rounding it. This usually leads to complicated calculations resulting 
in higher doses of the drug or an addition of agents that change the pH 
of surrounding media (13). One other factor that will influence the 
concentration gradient at the absorptive site is the pH gradient that 
exists between the fluid at the absorptive surface and the plasma (1, 
13, 17). 
Many times the ratio of ionized form of drug to nonionized form of 
drug will not be the same when comparing drug forms present in gastroin-
testinal secretions versus those of the plasma. A change of this type 
is going to affect the amount of drug administered and the eventual dis-
tribution of drug throughout all body fluids. Once the drug is adminis-
tered and the nonionized fraction of drug reaches the plasma, the 
establishment of an equilibrium of this drug form with all body fluids 
is begun. This equilibrium of the nonionized fraction of drug is going 
to be dependent on several factors. For instance, it has been shown 
that some drugs have high affinities for certain tissues of the body, 
i.e., liver, kidney, adipose tissues (13). This accumulation of drug 
within a tissue type will affect the amount of nonionized drug available 
for equilibrium. Another factor altering the available equilibrating 
moiety will be the degree of binding to plasma proteins. It is impera-
tive that the amount of drug given make up for the presence of active 
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drug moieties in tissues of high affinity", and the binding of drug to 
plasma proteins as well as a knowledge of how each of these will respond 
to shifts in equilibrium as the drug becomes inactive. 
Shifts in the equilibrium concerning the free nonionized fraction 
of drug may result from the excretion of drug or drug metabolites from 
the body. The method by which a drug will be excreted from the body 
varies with each drug. The organs associated with excretion of most 
drugs is the kidney and liver (13). Excretion by the kidney results 
from the ability of the kidney to filter the drug moieties from the 
plasma passing through the glomerular network of the kidney nephron (13, 
11). If the drug is such that it ·will not be reabsorbed through the 
renal tubular walls, then the drug passes out of the body in the same 
form that it existed in the plasma. However, many times the drug must 
be altered in some way so that eventually the body will be ridded of the 
drug. The other primary mechanism of ridding the body of the drug is 
hepatic excretion~ Many drug metabolites are formed in the liver and 
excreted in the bile, which passes out of the intestinal tract as a com-
ponent of fecal material (13). 
Secondary methods of excretion which facilitate the removal of drug 
from the body include various glands and their secretions. Examples of 
these encompass the salivary glands, sweat glands and the mammary 
glands of the female (13). The only form of drug that is excreted by 
these glands is the lipid soluble, nonionized moiety of a drug. Excre-
tion of drug from the sweat gland is of little concern in most cases. 
However, excretion of this drug form in secretions of either the sali-
vary glands or the mammary gland do deserve consideration. In the case 
of salivary excretion, the nonionized, lipid soluble fraction of the 
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dr~g will be excreted into the mouth and then swallowed putting it back 
into the stomach where it may be reabsorbed into the plasma. Recycling 
of the drug in this fashion will have an effect on the duration of 
action of the drug and should be a concern to those administering the 
drug. Excretion of the lipid soluable, nonionized fraction.of the drug 
through the secretions of the mammary gland is. a major concern to those 
administering the drug as well as for those who will consume the milk . 
obtained from the gland. Because of the possibility for excreting the 
active drug form into the milk, it is often stressed that drugs not be 
given to females producing milk that will be consumed. 
Biotransformation of Drugs 
The metabolism of a drug plays an important role in its therapeutic 
activity and toxicity (39). Detoxification of a drug refers to the 
changing of an active form of drug to an inactive form. This inactive 
form is the metabolite of the·drug and is the result of biotransforma-
tion by enzymes. The mechanism of biotransformation involves enzyme 
systems that change the structure of the drug so that the resulting com-
pound is more readily excreted from the body or has a different bio-
logical activity. Increasing the polarity of a compound is often the 
o~jective of biotransformation but sometimes, biotransformation leads to 
a change in structure-that only alters biological activity doing nothing 
to enhance the excretion of the drug. Transformation of this latter 
type often lead to an explanation of the side affects or after affects 
associated with various drugs. 
Me~hanisms of biotransformation involve Phase I reactions that oxi-
dize, reduce, or hydrolize, and Phase II reactions that lead to 
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conjugation of the drug so that a different compound results (17, 39). 
The enzymes catalizing both these types of reactions are found in 
association with various tissues (13). The amount of variance associ-
ated with these enzymes in different species often explains the 
differences in drug action as seen from species to species (12, 36). If 
·comparative studies in pharmacology are to tell us anything about the 
use of a drug in man, then the enzyme systems of man and the experi-
mental animal must be very similar to each other. 
The biotransformations that involve oxidation, reduction, and 
hydrolysis of the drug often involve enzymes of the normal metabolic 
pathways occurring within the liver microsomes (39). The number of oxi-
dations possible are quite numerous and may include such things as 
aromatic hydroxylation, N-oxidations, sulfoxidations, or aliphatic 
hydroxylation (14, 39). Reductions may be a nitroreduction, azoreduc-
tion, or an alchohol dehydrogenation (14). The hydrolysis reactions are 
like those involved in the metabolism of procaine resulting in the pro-
duction of p-aminobenzoic acid and diethylaminoethanol (14). The 
hydrolysis reactions are like those involved in the metabolism of 
procaine resulting in the produc.tion of p-aminobenzoic acid and di~thyl-
aminoethanol (14). 
The mechanisms involving Phase II reactions that result in the con-
jugation of the drug to some other chemicar moiety are generally more 
complex than the Phase I reactions. Phase II reactions are catalyzed by 
enzyme systems that seem to be primarily concerned with compounds the 
body regards as foreign (39). These reactions require some kind of 
"active" intermediate compound and a transferring enzyme. On the one 
hand the conjugating agent forms an active intermediate that is then 
combined with the drug through transferas_e activity. In other cases, 
the drug may become activated and then combine with the conjugating 
agent via the transferase. These two schemes are illustrated by 
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Any drug that has a glucuronate metabolite, follows the scheme involving 
a conjugating agent, glucuronic acid, an active in intermediate, uridine 
diphosphate glucuronic acid, and a glucuronyl transferase. An example 
of the second scheme of conjugation is the formation of hippuric acid 
from benzoic acid through benzoyl-CoA, the activated drug nucleotide. 
For this reaction xhe transferase is known as glycin~ N-acylase. The 
variation associated with different species in their ability to carry 
out these schemes is probably due _to the individual species ability to 
synthesize the necessary active intermediate nucleotides, the presence 
of transferring enzymes, or the availability of the conjugating agent 
within the species. An understanding of these differences reinforces 
the concept that comparative studies must be done so that the metabolic 
systems of the experimental animal will be very similar to the systems 
of the species to which the.drug will be given therapeutically. 
Mechanisms of Drug Action 
Comparative studies of drug behavior are valuable in that they may 
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provide insight as to how the drug is working on metabolic systems of 
the organism given the drug. Studies of this nature that employ 
techniques that allow for the measurement of certain parameters and how 
they change with administration of a drug or similar compoundsy may lead 
to the isolation of area of interest. These areas of interest usually 
involve the site of drug action at the cellular level as well as which 
of the constituents on the drug 1s responsible for the drug's action. 
Despite the importance of this type of information, analyses of this 
type are very difficult and time-consuming which keeps many researchers 
in other areas as well as those in this field slow 1n producing data. 
It is clear to those investigating this field of how and why drugs 
work that drugs taken to fight the invasion of certain organisms are 
usually highly specific for the invader as constrasted by a low toxicity 
to the host (30). This suggests that the mechanism of drug action 
involves biochemical differences between the host and the invading 
organism. These biochemical differences should be the result of 
differences in the metabolic systems of the two .or of differences 1n 
nucleic acid composition and sequence that determine the structures of 
proteins and enzymes found within each of the organisms (5). Knowledge 
of the nature of these differences provides·valuable information to 
those designing the structure of drugs that will be selective chemo-
therapeutic agents against invading organisms. 
Ways of isolating the areas suspected of being altered by a 
chemotherapeutic agent are numerous. There are certain techniques that 
seem to be very popular with those investigating how these biochemical 
differences respond to the application of drug. These techiques may 
involve an examination of how metabolic pathways are altered or how the 
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activity of the Na/K-ATPase dependent ion transport pump is affected. 
Much of the data gathered thus far seems to indicate that a large 
number of drugs inhibit enzymes involved in carbohydrate metabolism 
(reviewed by Beames [2], Cohen [5], and Mansour [21]). The deter-
mination of how a drug effects this metabolic pathway involves measuring 
the uptake and utilization of carbon sources, the presence of metabolic 
intermediates as well as the end products to be excreted. By measuring 
the occurance of the compounds in a ·control animal and then comparing 
these results to those obtained in the same fashion from an animal who 
had been given the drug of interest, it becomes possible to isolate 
points along the metabolic pathway that are altered by the presence of 
the drug. Once tpese points have been determined with some degree of 
certainty, the enzyme involved in the drug reaction can be isolated and 
collected for further study. Studies of this type not only help in the 
understanding of drug action, but also aid our understanding of meta-
bolic systems found in lower life forms. 
Many times these studies designed to measure the concentrations of 
metabolic substrates, intermediates, and end products do not always give 
an indication of the exact mechanism of action involved. Many of the 
enzymes involved in metabolic pathways respond to the internal cond-
itions of the cell (15). Consequently, any agent that disrupts the 
mechanisms involved in maintaining intraceLlular homeostasis will 
result in the breakdown of metabolic pathways. The Na/K-ATPase 
dependent ion transport pump is one of the mechanisms ·involved in 
homeostasis of cells due to the fact that this pump maintains the 
concentration gradient of ions necessary for normal enzymatic behavior. 
Interfering with the functional capacities of this pump leads to the 
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eventual death of the cell. 
By measuring the intracellular concentration of an ion maintained 
by this active pump and noting any changes that occur in response to the 
exposure of a drug, a statement about how and where the drug acts may be 
made (15, 19, 30). One of the techniques designed for th~ analysis of 
activity associated with this pump involves a study of ionic flux values 
associated with the cells of a tissue. A more complex technique 
involves intracellular measurements obtained from micropuncture of an 
individual cell. In each of these techniques, there is a control animal 
and an experimental animal, to which the drug of interest is given, so 
that differences in ionic concentrations that occur with the passage of 
time or changes in pH will not come into play when analyzing the data 
for significant differences due to the drug's effect. 
In flux studies, the usual procedure involves some radioactive ion 
whose flux is determined by the Na/K-ATPase dependent ion transport pump 
(15, 30). This ion must be one that is nondistinguishable by the mem-
brane in either its normal state or the radioactive state. The design 
of these flux studies is such that the uptake of this radioactive ion is 
correlated to the passages of time. This is achieved by taking segments 
of a tissue that are equal in weight and in their origin (all the seg-
ments used in these studies must be from the.same place in the animal). 
All of these alike segments are then placed in solutions containing the 
radioactive ion (isotope). At certain time intervals the tissues are 
removed from the solution fo~ analysis. The studies using tissue from 
the control animal will show the normal uptake of the isotope while 
tissue from the experimental animal will show how this uptake has been 
affected by the addition of the drug to the tissue. 
13 
By comparing the data and looking for significant differences between 
the two conditions, it becomes possible to determine if this pump is the 
site of drug action. 
In the above flux studies, the resulting data showed how much of an 
ion was taken up by a collection of cells but says nothing about what is 
happening within each of these cells. If we can measure the intra-
cellular ionic activities, then we can make a statement _about the 
concentration and electrochemical gradients that result from the meta-
bolic activities of the living system (19). One of the best ways to do 
this is to fabricate a glass electrode that has a tip diameter of 
5 to 10 microns and an electrical resistance of 8 to 13 megaohms. A 
microelectrode fashioned in this way can penetrate a single cell with-
out significant damage to the cell membrane. 
The design of this technique involves a complicated set-up where 
the tissue being investigated is suspended in a chamber of saline 
compatible with the tissue and the microelectrode is connected to a 
system of amplifie~s and chart recorders. Usually the microelectrode is 
mounted to micromanipulator to facilitate accurate impalement of the 
cell with the microelectrode (18, 19). By operating the micro-
manipulator it is possible to make several impalements of absorptive 
epithelial cells and to record signals from the microelectrode that are 
due to gradients across the cell membrane •. 
The way in which the 111icroelectrodes respond to the gradients 
involves a transfer of charge between a metal wire and an electrolyte 
solution at its interface (10). Once the microelectrode enters a 
solution of ions, there is a tendency for ions to move into or out of 
the microelectrode~ Movement of this type alters the equilibrium 
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existing at the metal/electrolyte interface. The magnitude of this 
shift is the signal that passes through an amplifier to give the final 
recorded signal (system reviewed in Nastuk 23). The recorded signal 
represents a potential difference between the microelectrode and some 
reference point in the solution (19). If the microelectrode is inserted 
into a solution that is separated from another solution by a membrane 
then the microelectrode will measure the potential difference across 
this membrane that is a function of the ionic distribution on either 
side of the membrane (16, 19). Unfortunately, measurements obtained 
from this microelectrode say nothing about the ions involved in the 
establishment of this potential difference. For specific ion analysis 
it is necessary to fill the tip of the microelectrode with an organic 
electrolyte having a high selectivity for a given ionic species (18). 
The procedure involving these ion specific microelectrodes is different 
from the aforementioned procedure involving reference electrodes. 
When employing microelectrodes that are specific for an ion, it 1.s 
necessary to standardize the electrode before its use 1.n biological 
systems. This.standardization procedure involves exposing the electrode 
to solutions of various concentrations o:.l; the ion exchanged by the resin 
within the tip of the microelectrode. The result of this exposure 
of the microelectrode to different concentrations of the ion is a cali-
bration curve that c~n be applied in the conversion of experimentally 
obtained potential measurements from this electrode to the concentration 
gradient it represents. Only after this curve is constructed will the 
data obtained in the impalement of biological cells be understood. It 
should be pointed out that these ion specific electrodes respond to the 
electrochemical gradient as well as the ionic concentration gradient. 
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For tliis reason it is necessary t'nat the membrane potentiitl measured by 
the reference electrode be subtratted from the.final· recorded signal 
obtained from the ion specific electrode if the actual potential 
difference between the ion specific electrode in the cytoplasm of the 
cell and the reference point in the bathing media is to be known (19). 
Both the flux studies and those of micropuncture designed to show 
whether or not the drug is interfering with the activity of the 
NA/K-ATPase active pump can be compared to those studies involving 
metabolic inhibitors effects on this pump (38, 40). After all, if the 
drug is interfering with the pump's ability to work, then it should be 
considered to be a metabolic inhibitor. Therefore, the changes in 
intracellular ionic concentrations or uptake of radioactive isotopes 
that occur in tissues exposed to known metabolic inhibitors should be 
representative of the kind of data seen in studies designed to identify 
agents of this type. By reviewing the literature on metabolic 
inhibitors and obtaining the above information as well as the chemical 
structure of these inhibitors, it is possible to analyze the presence or 
absence of similarities between the drug in question and a metabolic 
inhibitor which eventually leads to an idea of how the drug is acting. 
The experimental procedures mentioned thus far represent only a few 
of the many ways to determine mechanisms by which drugs act. Any 
technique that can measure differences occurring within a system in 
response to the passage of time or the presence of drug will be 
effective. Many times the type of technique employed is chosen in light 
of the type of equipment available to the laboratory perforn.iing the 
experiment. Other times the procedures involved in interpreting the 
data and the reliability of the data will determine the procedure used. 
In any case, a brief review of the literature will provide information 




INTRODUCTION TO HELMINTHS 
Helminth is a general ter,m that refers to several phyla of worms 
most of which are parasitic in nature. Helminthiasis refers to the dis-
eased condition brought on by the presence of worms in the body of a 
suitable host. Throughout the history of man these parasites have been 
a major etiological agent of infection (8). There is not a nation in 
this world whose .inhabitants are .not experiencing the problems associ-
ated with helminthiasis. Helminths invade the gastrointestinal tract, 
the circulatory system and the muscle systems of their hosts. They 
constitute a continual drain on.human energy resources that result in 
hindered economic growth. 
Relminthiasis .usually ·1ieS11lt:.s after. exposing the egg or larval form 
(l)f;tb,e, worm to .eert-ain tissu.es of the body. The most-common of these 
ane;·tbe. tissues of the m0Uth and feet. -On..ee the helminth has invaded 
t·he .. body cf its hast, a gene'J;'al wasting· awey of the 'body occurs in c.on-
jn.netien with feeliags. of n~sea, dizzUtesa, e.Jfh.austiou.and abdominal. 
diseo.JP;fort. Because of the prevalence of this condition throughout the 
worldiand the ameunt oi damag~ these parasites inflict on. their hosts, 
tlie.;desi:.gnnng·of drugs eff.eet.ivie against these,,o,rganisms has become.the 
maill, eonce·rn of many pharmaceutical engin.eers .• 
'· .· ©ne £actor that for many years hindered the developments. of "Ohemo-
tm:erapeutie ageuts against helminths was a lack of understanding of:the 
17 
18 
biochemistry and physiology of the helminths. Although the evidence 
gathered at this point does not give a complete picture of how helminths 
"work", it does provide enough information that aids in the development 
of drugs against these organisms. This information came from studies 
that indicated a divergency of the helminth's metaboli~ pathways from 
those of its host (21, 27, 28, 29, 30, 33). The divergent pathway that 
is of greatest interest is that of carbohydrat.e metabolism. 
In both host and parasite the catabolism of carbohycfrates provides 
the high energy levels necessary for the survival of the organisms. 
This utilization of "food" begins with the phosphorylation of glucose 
(2, 22, 29, 33). The phosphorylated glucose molecule is then acted upon 
by a number of glycolytic enzymes and the result is the conversion of 
glucose.into two molecules of phosphoenolpyruvate. In the host tissues 
phosphoenolpyruvate is formed into pyruvate by the enzyme pyruvate 
kinase ·and the reaction produces a nucleotide triphosphate (ATP). This 
enzyme is. not functional in many of the intestinal helminths (29, 33). 
Biochemists have analyzed the tissues·· of many helminths for the 
presence of glycolytic enzymes. What they found is that helminths 
catabolize,.glucose via the glycolytic pathway up to the point of 
. ,. 
phosphoenolpyruvate formation (2, 28, 29,_ 33). The metabolic pathways 
tha,t have b~t1:. de~eribed for. the ,tissues of ,4scar:i,s _S\J,um are represented 
in Figure 1. 
In helminths the reducing agent of this metabolic pathway is NADH 
(29). Because of the reduced activity of pyruvate kinase in helminths 
(Figure 1-C) phosphoenolpyruvate (PEP) is most often reduced by NADH and 
then subsequently combined with CO2 by the enzyme PEP carboxykinase 
(Figure 1-D) (29, 33). The oxaloacetate that results eventually forms 
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Figure 1. A Summary of Carbohydrate Metabolism for Ascaris Suum 
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malate which seems to be the substrate necessary for mitochondrial 
formation of ATP. The mitochondria of helminths do not possess oxida-
tive phosphorylating systems, but do have a means of producing ATP from 
malate (Figure 1 - A). One hal'f 0f the malate that enters the mitochon-
dria undergoes oxidative decarboxylation producing pyruvate and co2 as 
well as regenerating reducing power in the form of NADH (29). The 
enzyme:eatalyzing this reacti~n is called the•malic enzyme (29, 33). 
The regeneration of NADH allows for.the other one half of·malate to be 
reduced to succinate via fumarate and the enzyme, fumarate reductase 
(29). The formation of succinate occurs.with a concomitant generation 
of ATP. This pathway of anaerobic metaboli'sm is believed to be fairly 
common to most he.lminths and for this ·reason serves as the target for 
modern therapeutic agents used in .the t~eatment of helminthiasis. 
CHAPTER III •. 
ANTHELMINTICS 
The ultimate goal of pharmacological research is to produce chemo-
therapeutic agents that act selectively on the biochemical and physiolo-
gical mechanisms essential for the survival of the invading organisms 
(8, 30). In the case of the helminth parasites, these chemotherapeutic 
agents are referred to as anthelmintics. The development of these 
agents has been a primary concern to many pharmaceutical researchers due 
to the number of men and animals with this infection. Despite the 
importance of a vast need for effective agents that are highly selective 
for the invading parasite, but with low toxicity to the host, the devel-
opment of these agents has been slow. Only.recently have advances in 
this area been made as a result of newly discovered knowledge about the 
biochemistry o;fi the helminths. 
Winh,it::he knowledge of metabolic pathways within the parasite that 
diffe:tftomthose 0£ the host, the organic chemist is able to "target" 
the •drug• to"ic<:>nt'.l!ok points wiEliiia these helntintic· pathways. However, 
many·otfrthe drogs us~d therapeutically against invading organ.isms offer 
no, t:il:ue' as to their exact· mechanism o,f act ion. Studies, 1 ike those men-
tioned earlier for the determination of mechanisms of drug action, have 
been used by,many research laboratories to explain the anthelmintic 
naturetof various agents. For instance~ in a review by Coles (6) the 
mechanisms'ofac~ion for four anthelmintics most often used in 
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veterinary medicine. This revLew shows that Levamisole hydrochloride 
.and Pyrantel are anthelmintics that result in the paralysis of the hel-
minths while the class of drugs shown as the salicylanilides served to 
decrease the amount of ATP within the helminth with a single mode of 
action not likely. The fourth class of anthelmintics discussed in this 
review by Cole is the benzimidazoles. From the data collected by Cole, 
it appears that the benzimidazole compounds.work by interfering with the 
activity of the enzyme fumarate reductase. In a later discussion of 
these compounds, evidence will be presented which suggests that the ben-
zimidazole called mebendazole, also interferes with the integrity of the 
membranes of the intestinal epithelium. 
The majority of anthelmintics used therapeutically are administered 
orally whether they are meant to treat parasites of the gastrointestinal 
tract or those of the circulatory system. In most cases, there is a 
rapid absorption of a portion of the drug. Very rarely is the entire 
amount of drug present in the stomach or intestine absorbed. 0nce this 
absorbed dli'ug :r:eaches the plasma it becomes equally distributed through-
cf>Ufi all t.he body fluids. Distribution of this type facilitates the ter-
mi'nation .. ef any larval forms migrating within the body. The biotrans-
formatioil •of absorbed anthelmintic is geneli'ally very rapid witih the 
metabolilte .having oo biological activity. ~e liver is generally the 
organ of bietraasfo:rmation while the kidney is the organ responsible for 
e:xc1:etdng the .inaotive metabolite from the body. That portion of the 
drug net absorbed from the gastrointestinal tract will pass out of the 
body as a component of the feces (11, 12, and 15). 
']he to~ioity; generally associated with anthelmintic agents is 
minimal.· '£his,;,sh0uld come as no surprise in light of the prev:ious 
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discussion of "targeting" chemotherapeutic agents to metabolic systems 
not found in the host. Designing the drug in the form of an active sub-
strate of helminth metabolism ensures that it will be absorbed into the 
parasite and regarded as foreign by the host leading to a biotransforma-
tion of the agent that enhances its excretion. Despite how this sounds, 
it is possible to experience abdominal distress, nausea, and diarrhea if 
·the dose given is higher than the one suggested therapeutica!ly. 
Benzimidazoles 
From the many years of research in anthelmintics came a compound 
that had a five-membered ring nucleus and a heterocyclic compound 
substituted at the number two position (4). This group of compounds had 
a high biological activity against invading parasites. The five-
membered ring nucleus is known as the benzimidazole nucleus. These 
compounds are potent chemotherapeutic agents against all forms of the 
helminth, i.e., the larval, adult and ovicyte stages (7, 25). 
The benzimidazole compounds are not generally soluble in water 
(23). Therefore, something must be done to compensate for this, i.e., 
administer in oil, alter the molecule so that solubility is increased or 
adjust the amount of compound given so as to assure adequate absorption. 
Benzimidazole compounds behave like other anthelmintics in that they are 
evenly distributed i~ the body fluids, rapidly transformed into their 
metabolites and excreted by the kidney (34, 35). 
At the present time, there are four benzimidazole compounds of 
interest to pharmaceutical researchers (36). These are thiabendazole, 
mebendazole, cambendazole and parbendazole (Figure 2). Despite the 
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Figure 2. Benzimidazole Structure and Biological Activity at 
Therapeutic Dosage Levels 
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mechanism by which these drugs act. The one benzimidazole compound that 
has been widely studied is mebendazole. 
Methyl-5(6)-benzoyl-2-benzimidazole carbamate or mebendazole was 
originally studied for its effect on glucose uptake and glycogen storage 
within treated helminths (36). The more recent investigations of this 
drug, like those of Borgers et al. (3) and Van den Bossche (37), have 
indicated that there are ultra-structural changes occurring within the 
cells exposed to mebendazole. These changes have to do with the trans-
port of secretory granules within these cells. Van den Bossche 
sequenced the changes he saw as the disappearance of microtubules occur-
ring first, followed by a block in the transport of secretory granules 
as seen by an accumulation of these structures in the cytoplasm and 
finally, a necrosis of the cytoplasm (37). The disappearance of micro-
tubules in the intestinal cells of Ascaris Suum was also observed by 
Borgers and his associates as seen in electromicrographs of the effected 
tissue. In view of this evidence, it is generally accepted that the 
mechanism of action for mebendazole is an interference of microtubular 
structures by binding to the tubulin component of these structures (6). 
The similarity of cambendazole and parbendazole to mebendazole 
(they all have similar substituents as well as carbamate activity) 
should lead to the determination that these two compounds act on cells 
in the same fashion as mebendazole (36). Thiabendazole, on the other 
hand, does not exhibit any carbamate activity. Early studies involving 
the effects of thiabendazole on organisms seemed to indicate that the 
enzyme fumarate reductase was being affected. However, recent evidence 
indicates that the larval forms acted upon by thiabendazole do not 
contain the enzyme fumarate reductase (32). Since the absence of this 
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enzyme cannot account for the mechanism by which thiabendazole is 
working in this stage of helminth development, there must be other ways 
that this drug can affect living systems. With the amount of work being 
done on this drug by a number of laboratories, it should not be long 
before we clearly understand the mechanism of action for thiabendazole. 
CHAPTER IV 
SUMMARY 
Pharmacology is the science that studies the interactions of 
chemical agents and living systems. This science has been known to man 
for many thousands of years. As it exists today it is a science that 
receives contributions from a number of different areas, including 
biochemistry, physiology and pathology. This cooperative nature of 
pharmacology has lead to an enhanced understanding of the pharmacody-
namics of certain drugs. 
The pharmacodynamics of a drug involve the mechanisms by which the 
drug is absorbed, distributed, excreted, metabolized and, most 
importantly, acts at the cellular level. Each of these pharmacodynamic 
characteristics will behave in a fashion that is determined by the 
chemical structure of the drug. All of these characteristics accom-
panying a drug must be taken into consideration when deciding how much 
of the drug should be given to attain therapeutic levels of the drug in 
the body of an individual. 
Determining the ~xact mechanism of action associated with any drug 
is one of the hardest experimental problems to approach. The techniques 
designed for such an investigation are numerous with three such 
techniques being reviewed in this paper. The three techniques encom-




Throughout the world there exists the problem of man and domestic 
animals being infected with parasitic helminths, or worms. In order 
that drugs can be specifically developed for the treatment of this 
condition, advances in the knowledge of helminth biochemistry had to be 
made. The knowledge gained from scientists investigating metabolism of 
helminths indicated that these parasites are anaerobic in nature as 
opposed to the aerobic nature of their hosts. Information of this kind 
has become a valuable tool for the organic chemists specializing in the -
designing of drugs specific for these anaerobes. The resulting col-
lection of drugs are known as anthelmintics. 
Chemotherapeutic agents used as anthelmintics are generally rapidly 
absorbed from the gastrointestinal tract, evenly distributed, quickly 
metabolized, and excreted in the urine. Also associated with these 
compounds is a low level of toxicity to the host. 
A class of anthelmintics that is a major source of treating helmin-
thiasis (the condition of having helminths) is the benzimidazoles. 
Included in this class of drug is thiabendazole, mebendazole, cambenda-
zole and parbendazole. The methods of absorption, distribution, 
metabolism and excretion in the host are very similar to those already 
mentioned above. The interesting thing about the benzimidazole com-
pounds is the mystery of how they work at the cellular level. The pop-
ular theory of how mebendazole works invol¥es the binding of this 
compound to the tubulin component of microtubules which blocks micro-
tubule formation. Due to the similarity of cambendazole and 
parbendazole to mebendazole, further investigations of these two com-
pounds should indicate similar mechanisms of action with mebendazole. 
The amount of work that needs to be done with thiabendazole in order to 
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determine its mechanism of action is significant, but with the number of 
investigators involved, results should be obtained within the near 
future. 
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